Marex Group Plc (MRX) Quality Analysis

MRX GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

MRX Profitability

Profitability trend analysis coming soon

MRX Growth

Growth trend analysis coming soon

MRX Financial Health

Financial health indicators coming soon

MRX Quality & Fundamental Analysis

Marex Group Plc (MRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Marex Group Plc's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Marex Group Plc has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of 15.31% and a return on equity (ROE) of 0.00%. Return on assets (ROA) stands at 0.00%.

The debt-to-equity ratio is 15.33, with a current ratio of 1.09. Operating margin is 19.76%.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Marex Group Plc is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.